Stem Cell Research Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stem Cell Research

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SnowShredder who wrote (34)	3/5/2004 6:54:01 AM
From: SnowShredder	Read Replies (1) of 495

<snip> After 11 patients had been followed up for six months, it was found the seven who received stem cells plus G-CSF had improved heart function. But five of the seven, and two of three who received G-CSF alone, experienced in-stent restenosis - where coronary artery narrows again, despite the stent treatment. <snip> I wonder if a drug coated stent would prevent this from happening? What is the frequency and time of restenosis in normal stent procedures? Found something... biomedcentral.com <snip> The prevalence of ISR is estimated between 10% and 80%, depending on the definition used and several vessel- and patient-specific characteristics [6] ... The greatest tendency for the development of neointimal proliferation and ISR occurs between 1 and 3 months after the procedure, with minimal progression thereafter [9]. Between 6 months and 3 years after the procedure, there may be a slight improvement in luminal diameter [9,10]. Similarly, target site revascularization after the first year after coronary stenting occurs only sporadically [9,11]. The incidence and time course of restenosis after emergency coronary stenting are similar to those after elective stenting [12]." <snip> Best of Luck, SS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next